Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s New Criminal Investigations Chief Wants Global Reach

This article was originally published in The Tan Sheet

Executive Summary

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.

You may also be interested in...



US FDA’s OCI Director Is Leaving For Private Practice

George Karavetsos’ last day is Jan. 20, which coincidentally is the start of the Trump Administration. Office of Criminal Investigations has been subject of recent Congressional scrutiny.

FDA's Beleaguered Criminal Investigations Unit Now Facing Congressional Scrutiny

After staff complain about becoming the 'Botox police,' a House committee is asking FDA for an update on two previous reports raising issues of management and morale in the Office of Criminal Investigations.

FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts

FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel